TrialRMD open2026

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.

Roy Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.